Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase-4 inhibitor Linagliptin: A subanalysis from a randomized, placebo-controlled trial (RELEASE study)Boer, S. A., Reijrink, M., Abdulahad, W. H., Hoekstra, E. S., Slart, R. H. J. A., Heerspink, H. J. L., Westra, J. & Mulder, D. J., 27-Mar-2020, In : Diabetes obesity & metabolism. 6 p.
Research output: Contribution to journal › Article › Academic › peer-review
- Translational Immunology Groningen (TRIGR)
- Cardiovascular Centre (CVC)
- Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)
- Groningen Kidney Center (GKC)
- Groningen Institute for Organ Transplantation (GIOT)
- Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)
Angiogenic T (Tang) cells are mediators of vascular repair, and are characterized by surface expression of CXCR4. This receptor for stromal cell-derived factor-1 alpha (SDF-1 alpha) is cleaved by dipeptidyl peptidase-4 (DPP-4). Tang cell levels were investigated in people with type 2 diabetes mellitus (T2DM) compared with matched healthy controls and after treatment with the DPP-4 inhibitor Linagliptin. People with T2DM were randomized to 5 mg/day Linagliptin (n = 20) or placebo (n = 21) for 26 weeks. Tang cell frequency was identified in peripheral blood mononuclear cells (CD3(+)CD31(+)CXCR4(+)) and levels of endothelial progenitor cells (EPCs) (CD34(+)CD133(+)KDR(+)) were also assessed in whole blood. Circulating Tang cell levels were significantly lower in people with T2DM compared with the healthy control group. SDF-1 alpha levels increased significantly in Linagliptin-treated people with T2DM compared to placebo, and a trend was observed in change of Tang cell levels, while EPC count did not change. In conclusion, circulating Tang cell levels were considerably lower in people with T2DM, while a trend was observed in recruitment of Tang cells after 26 weeks of treatment with Linagliptin. These data suggest that DPP-4 inhibitors may potentially exert beneficial effects on bone marrow-driven vascular repair.
|Number of pages||6|
|Journal||Diabetes obesity & metabolism|
|Publication status||Published - 27-Mar-2020|
- angiogenic T cells, dipeptidyl peptidase-4 (DPP-4) inhibitors, Linagliptin, stromal cell-derived factor-1 alpha (SDF-1 alpha), type 2 diabetes mellitus, ENDOTHELIAL PROGENITOR CELLS